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Abstract
Background: Among birch pollen allergic patients up to 70% develop allergic reactions to Bet v 1-homologue food
allergens such as Api g 1 (celery) or Dau c 1 (carrot), termed as birch pollen-related food allergy. In most cases, specific
immunotherapy with birch pollen extracts does not reduce allergic symptoms to the homologue food allergens. We
therefore genetically engineered a multi-allergen chimer and tested if mucosal treatment with this construct could
represent a novel approach for prevention of birch pollen-related food allergy.
Methodology: BALB/c mice were poly-sensitized with a mixture of Bet v 1, Api g 1 and Dau c 1 followed by a sublingual
challenge with carrot, celery and birch pollen extracts. For prevention of allergy sensitization an allergen chimer composed
of immunodominant T cell epitopes of Api g 1 and Dau c 1 linked to the whole Bet v 1 allergen, was intranasally applied
prior to sensitization.
Results: Intranasal pretreatment with the allergen chimer led to significantly decreased antigen-specific IgE-dependent b-
hexosaminidase release, but enhanced allergen-specific IgG2a and IgA antibodies. Accordingly, IL-4 levels in spleen cell
cultures and IL-5 levels in restimulated spleen and cervical lymph node cell cultures were markedly reduced, while IFN-c
levels were increased. Immunomodulation was associated with increased IL-10, TGF-b and Foxp3 mRNA levels in NALT and
Foxp3 in oral mucosal tissues. Treatment with anti-TGF-b, anti-IL10R or anti-CD25 antibodies abrogated the suppression of
allergic responses induced by the chimer.
Conclusion: Our results indicate that mucosal application of the allergen chimer led to decreased Th2 immune responses
against Bet v 1 and its homologue food allergens Api g 1 and Dau c 1 by regulatory and Th1-biased immune responses.
These data suggest that mucosal treatment with a multi-allergen vaccine could be a promising treatment strategy to
prevent birch pollen-related food allergy.
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Introduction
One of the most common type I pollionosis is caused by the
airborne allergens of birch pollen (BP). In Europe, more than 70%
of BP-allergic patients develop an immediate hypersensitivity
reaction against pollen-related food allergens, termed as birch
pollen-related food allergy (BPRFA) and clinically manifested as
oral allergy syndrome (OAS). IgE antibodies specific for Bet v 1,
the major BP allergen, cross-react with epitopes of homologous
food allergens such as Mald1 (apple), Cora1 (hazelnut), Api g 1
(celery), or Dau c 1 (carrot) [1,2]. Due to this cross-reactivity, Bet v
1-specific IgE can induce hypersensitivity reactions towards these
food allergens. The symptoms of the BPRFA are usually restricted
to the oral cavity and can range from swelling and itching of lips,
tongue, soft palate and pharynx to systemic reactions such as
urticaria, asthma or even anaphylaxis [3,4]. Most of these patients
also display food induced symptoms outside the BP season,
indicating that homologous food allergens provide a perennial
boost of BP-specific immune responses [5].
For BP mono-sensitized individuals common specific immuno-
therapy (SIT) is well established and is regarded as a successful
therapy. However, for treatment of patients with multiple
sensitivities or BPRFA, SIT has low efficacy and is associated
with an increased risk of anaphylactic side-effects [1,6,7].
Improving this treatment could either be achieved by the
application of well defined recombinant single allergens or
a mixture thereof, or allergen peptides according to the patient
T cell recognition pattern. Additionally, exploiting different routes
of vaccination, e.g. changing the subcutaneous to a less invasive
administration via the mucosa (i.e. oral, nasal, sublingual) could
improve the efficacy of this treatment [8].
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recombinant allergens prevented allergic sensitization in mono-
sensitized mice [9]. In poly-sensitized mice, however, application
of a mixture of recombinant antigens did not efficiently elicit
protective effects [8,10]. More recently, we demonstrated that
mucosal application of either a multi-peptide construct, covering
the immunodominant T cell epitopes of the major birch and grass
pollen allergens, or a multi-allergen chimer, consisting of the
scaffold allergen Bet v 1 in its native conformation anchoring two
or more immunodominant peptides from major grass pollen
allergens, prevented multi-sensitization against these allergens
[8,10].
In the current study we established a model of BPRFA in poly-
sensitized mice to validate the protective effects of mucosal
treatment with a respective chimer. For this purpose we designed
a pollen-food-allergen chimer consisting of Bet v 1, acting as
a potent tolerogen, fused with additional immunodominant
peptides of its homologous food allergens Api g 1 from celery
and Dau c 1 from carrot. Our data provide evidence for the
efficacy and underlying mechanisms of mucosal treatment with
this chimer in preventing local and systemic Th2 immune
responses in poly-sensitized mice.
Methods
Animals
Female 7-week-old BALB/c mice (n=12 per group) were
obtained from Charles River (Sulzfeld, Germany). All experiments
were repeated 3 times.
Ethics Statement
The animal studies were performed according to institutional
guidelines for animal use and care. The study was approved by the
Animal Experimentation Ethics Committee of the Medical
University of Vienna and the Ministry of Science and Research
(GZ 66.009/229-BrGT/2005; GZ 66.009/35-II/10b/2010).
Antigens and Antibodies
Recombinant Bet v 1.010, Api g 1.0101 and Dau c 1.0103 were
obtained from Biomay AG (Vienna, Austria). Birch pollen (BP)
from Betula verrucosa was purchased from Allergon (Va ¨linge,
Sweden ), and protein extracts of BP, celery (Apium graveolens) and
carrot (Daucus carota) were prepared as previously described
[11,12].
Anti-TGF-b, anti-IL-10R and anti-CD25 blocking antibodies
were produced in house at the University of Edinburgh, UK (and
provided by R. Maizels). Rat IgG isotype control antibody was
used (Sigma-Aldrich).
Epitope Mapping Studies
For T cell epitope mapping a panel of 48 peptides of Api g 1
and 48 peptides of Dau c 1 were used (provided by B. Bohle).
Spleen cell suspensions from Api g 1 or Dau c 1 immunized mice
were incubated with 5 mg/well of each of the peptides, which
overlapped for three amino acids (neighbours sharing nine
residues) spanning the whole amino acid sequence of the
respective antigens. Proliferative responses were measured accord-
ing to previous description [12].
Construction of the Birch Pollen–food–chimer Expression
Plasmid
Complementary templates from Api g 1 (Genbank Access
number: Z48967) and Dau c 1 (Genbank Access number: Z84376)
respectively, were used to amplify the identified immunodominant
encoding regions by PCR (cDNA templates were provided by K.
Hoffmann-Sommergruber). Api g 1-T cell epitope specific primers
were designed including NcoI and EcoRI restriction sites (Api g 1
fwd 59-CATGCCATGGATGGAGTTAACAAGGAG-39, Api g
1 rev 59-ATGAATTCAACATGGTTTTCAATGGA-39; restric-
tion sites underlined); Dau c 1-T cell epitope specific primers were
designed including HindIII and XhoI restriction sites (Dau c 1 fwd
59-ACCAAGCTTGCCGTGGTTCCTGAAGAG-39, Dau c 1
rev 59-CCGCTCGAGTTAATTAGCAATGAGGTAGGC-39).
For construction of the Api g 1-Bet v 1-Dau c 1-chimer we
ligated the PCR amplicons of Api g 1 and Dau c 1 into the
respective restriction sites on the 59- and 39-end of a pHis Parallel
2 - Bet v 1 plasmid, equipped with a hexahistidyl (66His) affinity
tag as previously described [8]. Subsequent DNA sequence
analysis (GATC Biotech, Konstanz, Germany) verified correct
sequences and the integrity of open reading frame.
Expression, Purification and Refolding of Recombinant
Api g 1-Bet v 1-Dau c 1-chimer
The Api g 1-Bet v 1-Dau c 1-expression plasmid was
transformed into electrocompetent BL 21(DE3)plysS E. coli cells
(Invitrogen, NV Leek, Netherlands) and grown in LB/1 mM
ampicillin medium at 37uC under vigorous shaking until an optical
density (OD600) of 0.7. Expression was induced by adding
0.001 mol/L isopropyl b-D-thiogalactopyranoside (IPTG) and
incubation continued for additional 3 hours before harvesting.
66His-tagged r Api g 1-Bet v 1-Dau c 1-chimeric protein was
produced in inclusion bodies and therefore purified from E. coli
lysate under denaturing conditions. Cells were solubilized in
denaturating lysis buffer (8 mol/L urea, 0.1 mol/L NaH2PO4,
0.01 mol/L tris, pH 8.0) and purified by nickel nitrilotriacetic acid
affinity column (GE Healthcare, Uppsala, Sweden).
Purified protein fractions were monitored by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), pooled
and refolded by stepwise dialysis against 0.02 mol/L NaPO4,
pH 8.0 while gradually reducing urea concentration from 6 mol/
L to 0 mol/L. After a final dialysis against 0.01 mol/L NaPO4,
pH 7.2, Api g 1-Bet v 1-Dau c 1-chimer was lyophilized and
stored at 220uC.
Concentration of bacterial endotoxins was determined using the
Limulus amebocyte lysate assay (QCL-1000, Cambrex, Walkersville,
MD, USA) according to the users manual. Endotoxins were
removed using the EndoTrap Blue affinity column (Profos,
Regensburg, Germany) according to the manufacture’s instruc-
tions. Protein concentration was determined using the bicinchro-
nic acid protein assay (Pierce, Rockford, IL, USA).
Protein Analysis
Physiochemical identification and characterization of the
recombinant construct was done by preparative HPLC and mass
spectrometry (piCHEM, Graz, Austria), and secondary structure
by far UV light circular dichroism spectroscopy (CD), as
previously described [8].
Immunological characterization was done by immunoblot
analysis using a monoclonal mouse anti-Bet v 1 IgG antibody
(BIP1, 1/10), sera from 3 BP allergic patients with concomitant
BPRFA containing Api g 1-, Dau c 1-, and Bet v 1-specific IgE (1/
5) or mouse sera from a chimer-tolerized, poly-sensitized mouse
(1/5). For detection secondary rat anti-mouse IgG1 antibody (1/
500; BD Pharmingen, San Diego, CA, USA) followed by an
alkaline phosphatise-conjugated goat anti-rat IgG (1/2000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), or alkaline
phosphatase-conjugated mouse anti-human IgE (1/1000; Phar-
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Negative controls with sera from untreated mice and non-allergic
patients, or buffer control were run in parallel.
Animal Treatment
Allergy prevention in mono-sensitized mice with either
rBet v 1, rApi g 1 or rDau c 1. Mono-sensitization was
performed by 3 intraperitoneal (i.p.) injections (day 22, 36, 50) of
5 mg per Bet v 1, Api g 1 or Dau c 1 adsorbed to aluminium
hydroxide (Al(OH)3; Serva, Heidelberg, Germany) in 14 day
intervals, adapted from Hufnagl et al. [13]. For prevention of
allergic sensitization 10 mg of either of the allergen Bet v 1, Api g 1
or Dau c 1 were intranasally (i.n.) applied in 30 ml of 0.9% NaCl 3
times in 7 day intervals (day 0, 7, 14), prior to mono-sensitization,
adapted from Wiedermann et al. [12]. Samples were taken one
week after the last treatment (day 57).
Allergy prevention in poly-sensitized mice with a mixture
of all three allergens. Poly-sensitization was performed by
applying a mixture of Bet v 1, Api g 1 and Dau c 1, 5 mg each
adsorbed to Al(OH)3 as described above. For prevention of poly-
sensitization mice were i.n. pretreated with a mixture of 10 mg
each of Bet v 1, Api g 1 and Dau c 1, in 30 ml of 0.9% NaCl.
Allergy prevention and poly-sensitization protocols were adapted
from Hufnagl et al. [10].
Allergy prevention with the birch pollen-food chimer in
poly-sensitized mice. Intranasal pretreatment with the BP-
food chimer was performed by using 15 mg of the chimer in 30 ml
of 0.9% NaCl per application (adapted from Wild et al. [8] ) as
described above, prior to poly-sensitization. Control mice were i.n.
sham-treated with 30 ml of 0.9% NaCl prior to poly-sensitization.
One week after the last i.p. immunization, mice were sublingually
(s.l.) challenged with a mixture of BP extract, carrot extract and
celery extract, by applying 100 mg each in 15 ml of 0.9% NaCl
with a pipette under the tongue of the mice. To prevent
swallowing of the extracts mice were fixed in the scruff during
and until 20 seconds after treatment. Mice were challenged on 3
consecutive days in 24 hour intervals (day 57, 58, 59). 24 hours
after the last treatment mice were sacrificed (day 60) (Fig. 1).
In vivo application of neutralizing antibodies. In some
experiments, i.n. chimer-pretreated and poly-sensitized mice were
i.p. injected with 0.5 mg of blocking antibodies. Anti-CD25 was
applied prior poly-sensitization (day 15) (adapted from Leech et al.
and Wilson et al.) [14,15], anti-TGF-b before s.l. challenge (day
56) (adapted from Taher et al. [16]), and anti-IL-10R was injected
before poly-sensitization (day 19) and before s.l. challenge (day 56)
(adapted from Taher et al., Leech et al. and Wilson et al.
[14,15,16]). Pretreated and poly-sensitized control mice were
sham-treated with 0.5 mg isotype control antibodies.
Sampling
Blood samples were taken before treatment and on the day of
sacrifice by tail bleeding. Sera were collected and stored at 220uC
until analysis. On the day of sacrifice cell suspensions from spleen,
cervical lymph nodes (CLN) and NALT were prepared as
described [12,17,18]. Additionally, sublingual tissues (SLT) and
buccal mucosa (BM) were prepared by excising the whole
mandible from the head and dissecting the cheek skin and the
tongue with the floor of the mouth (SLT). The cheek skin was
stretched and mucosal tissue was scraped off with a scalpel and
collected in RNAlater buffer (Qiagen, Valencia, CA) for RNA
isolation. SLT was separated from the tongue and stored in
RNAlater buffer as well [19].
Allergen-specific Antibody Levels and Total IgA in Serum
Microtiter plates (Nunc, Roskilde, Denmark) were coated with
each of the recombinant allergens Bet v 1, Api g 1 or Dau c 1
(5 mg/mL) prior to incubation with sera in dilutions of 1/500 for
antigen-specific IgG2a and 1/10 for antigen-specific IgA de-
tection. Rat anti-mouse IgG2a or IgA antibodies (1/500,
Pharmingen) were used, followed by peroxidase-conjugated mouse
anti-rat IgG antibody (1/2000, Jackson Immuno Lab, West
Grove, PA) [12]. Results show the OD values after subtraction of
baseline levels from pre-immune sera.
For determination of total IgA levels in sera, microtiter plates
(Nunc) were coated with rat anti-mouse IgA (1/250, clone C10-3,
Pharmingen) and incubated with 1/100 diluted sera. For detection
biotinylated anti-mouse IgA (1/1000, clone C 10-1, Pharmingen)
antibody, streptavidin (1/10000) and ABTS substrate were used.
Results are shown in ng/mL after subtraction of baseline levels
of pre-immune sera.
Rat Basophil Leukemia Cell Mediator Release Assay (RBL
Assay)
For measurement of functional allergen-specific IgE, rat
basophil leukemia (RBL) cells (RBL-2H3 cell line, ATCC, No.
CRL-2256) were incubated with sera obtained from pretreated
and poly-sensitized mice at dilutions of 1/10, 1/100 and 1/300.
Degranulation of RBL cells was induced by adding 0.03 mg of Bet
v 1, Api g 1 or Dau c 1 diluted in 100 ml Tyrodes buffer.
Figure 1. Experimental design. Mice were intranasally pretreated with either the chimer (chimer-treat) or sham-treated (poly-sens) 3 times in 7
days intervals followed by 3 intraperitoneal sensitizations with a mixture of rBet v 1, rApi g 1 and rDau c 1 in 2 weeks intervals. Thereafter, mice were
sublingually challenged with a mixture of BP, celery and carrot extracts on 3 consecutive days.
doi:10.1371/journal.pone.0039409.g001
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hexosaminidase activity as previously described [13].
Cytokine Production
IL-4, IL-5, IFN-c and TGF-b production was measured in
spleen (5610
6 cells/well), CLN (5610
5 cells/well) and NALT
suspensions (5610
5 cells/well) incubated for 48 hours with each
allergen (15 mg/well) as described [17]. Levels of IL-4, IL-5 and
TGF-b were measured with ELISA kits (eBioscience, San Diego,
CA, USA), IFN-c levels were measured as previously described
[20]. All cytokine levels are shown in pg/mL after subtraction of
baseline levels of unstimulated cultures.
Magnetic Sorting of CD4
+CD25
+ Tregs and CD4
+CD25
2 T
Effector Cells
CD4
+CD25
2 T effector cells (Teff) and CD4
+CD25
+ Treg cells
were isolated from pooled spleen cells of chimer-pretreated or
control poly-sensitized mice, with the MACS CD4
+CD25
+ Treg
isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany),
according to the manufacturer’s protocol. The purity of sorted
cells was acquired by flow cytometry using a BD FACSCalibur
(BD Biosciences Pharmingen) and analysed by FlowJo software.
Treg Suppression Assay
CD4
+CD25
2 Teff cells (5610
4) were cocultured in U-bottom
96-well plates with CD4
+CD25
+ Treg cells in various ratios (1/2,
1/8, 1/16). The cells were stimulated with 1 mg/mL anti-mouse
CD3 (eBioscience) and 5610
4 irradiated (3000 rad) splenocytes at
37uC for 3 days. For the last 16 hours of culture, cells were pulsed
with 0.5 mCi
3H-thymidine/well (Perkin-Elmer, Wellesley, MA,
USA), harvested and proliferative responses were measured by
scintillation counting (1450 Microbeta Liquid Scintillation and
Luminescence counter, Perkin-Elmer). Results are expressed as
absolute counts per minute (cpm). The percent suppression
mediated by Treg cells was calculated by the following formula:
[(cpm of Teff alone – cpm of Teff treated with Treg)/cpm of Teff
cells alone]*100.
Quantification of mRNA Expression by Real-time RT-PCR
Total RNA from NALT was isolated from equal pooled cell
suspensions. Total RNA extracted from RNAlater-stabilized,
pooled SLT and BM was homogenized in liquid nitrogen prior
to purification by using RNeasy Minikit combined with DNase
digestion (RNase-free DNase Set, Qiagen). The concentration of
extracted RNA was measured by NanoDrop ND-1000 spectro-
photometer (PeqLab, Erlangen, Germany), RNA probes were
standardized and then reverse-transcribed into cDNA using
iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA, USA).
Gene expression was determined by quantitative real-time RT-
PCR using LightCyclerH FastStart kit with TaqManH or
CYBRGreen according to the manufacturer’s instructions (Roche,
Mannheim, Germany) on a LightCyclerH instrument 1.2 (Roche).
For quantification of TGF-b, IL-10 and Foxp3 mRNA, pre-
designed TaqManH assays were used. Data are presented as the
relative ratio of the target genes to the housekeeping gene 5-
aminolevulinic acid synthase 1 (Alas1) (Universal ProbeLibrary (UPL)
probe #64, Roche) [21].
Statistics
Data are expressed as means 6 SEMs from 3 independent
experiments. For statistical analysis p values ,0.05 were defined
significant. Pair-wise comparison of sham-treated sensitized versus
pretreated groups was performed by using the Mann-Whitney U-
test and one-way ANOVA-test.
Results
Intranasal Pretreatment with Bet v 1, Api g 1 and Dau c 1
Alone or as a Mixture does not Suppress Immune
Responses Against All 3 Allergens
Mucosal application of Bet v 1 prior to intraperitoneal
polysensitization significantly reduced serum IgE responses as
measured by IgE-induced basophil degranulation to Bet v 1, but
not to Api g 1 or Dau c 1 (Fig. 2A). Similarly, mucosal application
of Api g 1 or Dau c 1 prior to poly-sensitization showed
significantly decreased IgE-induced b-hexosaminidase release only
for the respective allergen (Fig. 2A).
In poly-sensitized mice, mucosal pretreatment with a mixture of
all 3 allergens significantly reduced basophil degranulation to Bet v
1, but not to the homologous food allergens (Fig. 2B).
Construction and Characterization of the Birch Pollen-
food Allergen Chimer
Based on previous T cell epitope mapping experiments with Api
g 1 and Dau c 1 the immunodominant regions of these allergens
were selected for designing the Bet v 1-food allergen chimer. In the
case of Dau c 1 the immunodominant peptide detected in mice is
also a major T cell epitope in allergic patients [22]. The
immunodominant T cell epitope from Api g 1 (DGVNKEALTF-
DYSVIDGDILLGFIESIENHV, peptide 27) including a 66His-
tag was inserted at the N-terminus of the Bet v 1.0101 encoding
sequence. At the C-terminus the immunodominant T cell epitope
of Dau c 1 (AVVPEENIKFADAQNTALFKAIEAYLIAN, pep-
tide 47) was added (Fig.3A). Correct insertion of the templates was
checked by sequence analysis.
After purification and refolding of the chimer with a theoretical
mass of 27,6 kD, endotoxin levels of ,0,05 EU/mg of purified
protein were measured, which corresponds to baseline levels of
commercially available proteins [9].
Secondary structure elements of the chimer, analyzed by CD
spectra, were in good agreement with the spectra obtained from
rBet v 1 [8]. Only minimal variations due to the added peptides
(data not shown) were observed. Immunoblot analysis confirmed
that the conformation of Bet v 1 remained unchanged after linkage
of the peptides. The chimer was recognized by Bet v 1-specific
monoclonal antibody (BIP1, lane 3) and by IgE from sera of 3 BP
allergic patients with a BPRFA (lane 5, 6, 7) as well as IgE from
sera of a chimer-treated poly-sensitized mouse (lane 1). Negative
controls did not elicit any IgE binding to the chimer (lane 2, 8, 4,
9) (Fig. 3B).
Intranasal Pretreatment with the BP-food-chimer
Suppressed Humoral and Cellular Immune Responses in
Poly-sensitized Mice
Antibody responses. Intranasal pretreatment with the
chimer significantly reduced IgE-mediated basophil degranulation
to all three allergens in comparison to the untreated poly-sensitized
group (Fig. 4A). Moreover, Api g 1-, Dau c 1- and Bet v 1-specific
IgG2a antibody production was enhanced, indicating a shift
towards Th1 responses (Fig. 4B). Additionally, pretreatment with
the chimer increased serum levels of total and allergen-specific IgA
antibodies in comparison to poly-sensitized controls (Fig. 4C).
Cytokine production. Pretreatment with the chimer signif-
icantly decreased IL-5 levels in supernatants of allergen restimu-
lated spleen and CLN cell cultures (Fig. 5A). Additionally, the IgE
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spleen cell cultures of chimer treated mice compared to poly-
sensitized controls: IL-4 (pg/mL): polysens: Bet v 1-restimulated:
14,35622,60; Api g 1-restimulated: 43,92653,84; Dau c 1-
restimulated: 58,87664,83; chimer-treat: Bet v 1-restimulated:
5,0667,45; Api g 1-restimulated: 7,6168,14**; Dau c 1-
restimulated: 11,89613,70**; **p,0,01.
IFN-c production in spleen cell cultures was significantly
enhanced after Bet v 1 - but not after Api g 1 or Dau c 1 -
stimulations compared to poly-sensitized controls (Fig. 5B).
However, in the CLN (Fig. 5B), and also in the NALT (data not
shown) cultures, IFN-c production was significantly increased in
the pretreated mice after re-stimulation with all three allergens.
Prevention of Allergic Polysensitization with the Chimer
is Associated with Regulatory Mechanisms
The mRNA expression of TGF-b, IL-10 and Foxp3 in NALT
was enhanced in chimer-pretreated mice compared to poly-
sensitized controls (Fig. 6A). Increased Foxp3 expression was
detected in SLT and BM of chimer-pretreated mice (Fig. 6B).
Application of anti-TGF-b, anti-IL10R or anti-CD25 blocking
antibodies significantly abrogated the suppression of IL-5 and IL-4
production in spleen cell cultures of chimer-treated mice (Fig. 7A).
Furthermore anti-TGF-b treatment of chimer-treated mice led to
diminished antigen-specific and total IgA levels in sera (Fig. 7B).
Treg cells isolated from chimer-treated mice exhibited stronger
suppressive potential as Treg cells from poly-sensitized mice
(Fig. 8). The percent suppression mediated by Treg cells isolated
from chimer-treated mice was 4.8-fold higher (ratio 1/2) than
Tregs derived from poly-sensitized mice.
Figure 2. IgE-dependent allergen-specific basophil degranulation by sera. (A) ß-hexosaminidase release from (I.) rBet v 1-, (II.) Api g 1- or
(III.) Dau c 1-sensitized mice; each group was i.n. pretreated with rBet v 1 (black bars), rApi g 1 (light-grey bars), rDau c 1 (dark-grey bars) or sham-
treated (white bars). (B) ß-hexosaminidase release from mice i.n. pretreated with a mixture of rBet v 1/rApi g 1/rDau c 1 (black bars) compared with
poly-sensitized controls (white bars). **p,0.01.
doi:10.1371/journal.pone.0039409.g002
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Clinical data regarding the efficacy of specific immunotherapy
(SIT) with BP against pollen-related food allergies provide
controversial results: While it has been shown that SIT with BP
extract could achieve good effects in mono-sensitized patients [23],
SIT in multi-sensitized patients with BPRFA often provided only
limited success on the food-related symptoms [6,7,24]. Bucher et
al. attributed this observation to the reason that BPRFA is not only
caused by Bet v 1-cross reactive allergens, but also due to other less
well-defined cross-reactive food allergens, which are not included
in BP extracts used for SIT [2]. Along these lines, Bohle et al.
described the existence of exclusive food-specific T lymphocytes,
additionally to BP-reactive T cells in pollen-food multi-sensitized
patients and suggested this finding to be one of the reasons why
allergic symptoms of pollen-related food allergens are not
modulated by BP SIT [1].
Here we describe a murine model for BPRFA which enables us
to study the role of both IgE and T cells responses in sensitization
to Bet v 1 and Bet v 1-related food allergens as well as the efficacy
of prevention of multi-sensitization using a novel allergen chimer
covering the major T cell epitopes of Bet v 1, Dau c 1 and Api g 1
(Fig. 1, Fig. 3A).
In order to mimic the clinical situation of BPRFA with OAS,
mice were challenged sublingually with pollen and food extracts.
Our data show that the sensitization protocol led to systemic Th2-
biased immune responses as well as local immune responses to Bet
v 1, Api g 1 and Dau c 1. Similarly as seen in humans, we observed
that mucosal application of the single allergens, in particular with
Bet v 1, did not reduce the allergic responses to the related food
allergens indicating that other than Bet v 1 epitopes are necessary
for successful prevention of BPRFA (Fig. 2A). Furthermore,
a mixture of the allergens also did not suppress the immune
responses to all allergens (Fig. 2B). A similar negative interference
between several protein allergens was previously described by us,
when intranasally applying a mixture of birch and grass pollen
allergens aiming to prevent allergic poly-sensitization to these
allergens [8]. The failure to prevent allergic poly-sensitization with
the allergen mixture pointed out the necessity for creating multi-
allergen constructs.
Therefore, we engineered a pollen-food chimer, composed of
the Bet v 1 protein as scaffold for linkage of the immunodominant
T cell epitopes of Api g 1 and Dau c 1 (Fig. 3A). Of notice, these
immunodominant T cell epitopes in mice are located in regions of
the dominant T cell sequences of humans with BPRFA [22,25].
Mucosal application of the chimer led to a marked immuno-
modulation characterized by a shift towards Th1 immune
responses (increase in IgG2a) accompanied by a significant
down-regulation of allergen-specific IgE to all three allergens
(Fig. 4A/B). In accordance, reduced antigen-specific IL-4 and IL-5
levels versus significantly enhanced antigen-specific IFN-c levels
were observed in restimulated spleens and CLNs after chimer
pretreatment (Fig. 5). These findings are in line with our previous
studies in poly-sensitized mice using either poly-peptides, hybrid
peptides or allergen chimers for prevention of poly-sensitization
[8,10]. Additionally, intranasal pretreatment with the chimer
increased IgA antibody levels primarily in sera (Fig. 4C) and less at
the mucosal sites (data not shown). This might be explained by
a matter of increased systemic circulation due to the highly
vascularized tissue of the oral cavity, as it has been suggested in
humans [26]. Studies by Pilette et al. showed that successful SIT
positively correlates with increased serum IgA antibodies [27].
There is evidence that TGF-b plays a major role in IgA
Figure 3. Construction and characterization of the pollen-food-chimer. (A) Design of the pHis-parallel 2-chimer composed of Bet v 1 protein,
flanked by peptides from Api g 1 and Dau c 1. (B) Immunoblot: IgE binding to the chimer of sera from chimer-pretreated/poly-sensitized mice (lane 1)
and of BP allergic patients with BPRFA (lane 5, 6, 7), and of Bet v 1 monoclonal antibody (lane 3). Negative controls sera from untreated mouse and
non-allergic patient, or buffer control were run in parallel (lane 2, 4, 8. 9).
doi:10.1371/journal.pone.0039409.g003
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anti-TGF-b antibody to chimer-treated mice reduced IgA levels in
sera (Fig. 7B).
Regarding the mechanisms of chimer-induced immunomodula-
tion, we detected an upregulation of TGF-b, IL-10 and Foxp3
mRNA levels in the NALT (Fig. 6A). Additionally, increased
Foxp3 mRNA expression occurred in sublingual tissue and the
buccal mucosa (Fig. 6B). This is in line with our former data
showing that immunomodulation with a grass-birch pollen chimer
but also with Bet v 1 alone is mediated by Treg cells [8,9]. The
clinical relevance of this finding is supported by human studies
showing an increase of regulatory Foxp3-positive T cells in the
nasal mucosa of patients after successful systemic as well as
sublingual grass pollen SIT [30,31]. In the latter study it was
suggested that regulatory T cells either migrate from draining
lymph nodes to the sublingual tissue during SLIT or may be
Figure 4. Antigen-specific cellular and humoral responses in mice pretreated with the chimer and poly-sensitized control mice. (A)
IgE-mediated basophil degranulation. (B) Allergen-specific IgG2a antibodies in sera. (C) Total and antigen-specific IgA antibodies in sera. Chimer-
pretreated mice (black bars); poly-sensitized control mice (white bars). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0039409.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39409induced by local dendritic cell-T cell interactions after repeated
allergen exposure via the oral mucosa [31]. Furthermore, it was
shown that sublingual treatment with allergens led to induction of
IL-10 and TGF-b-releasing cells within the oral and nasal mucosa
[31].
Figure 5. Antigen-specific cytokine production in mice pretreated with the chimer and poly-sensitized mice. (A) IL-5 levels and (B) IFN-
c levels in supernatants of spleen and cervical lymph nodes (CLN) cell cultures after antigen stimulation. Chimer-pretreated mice (black bars); poly-
sensitized control mice (white bars). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0039409.g005
Figure 6. mRNA expression levels of regulatory markers on inductive and local effector sites. (A) TGF-b, IL-10 and Foxp3 mRNA
expression in NALT, and (B) Foxp3 mRNA expression in SLT and BM of chimer-pretreated mice (black bars), shown as relative values in comparison
with poly-sensitized controls (white bars). Data are presented as relative ratio of the target genes to the housekeeping gene Alas1.
doi:10.1371/journal.pone.0039409.g006
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chimer-induced regulatory T cells in our BPRFA model,
neutralizing antibodies against CD25
+ T cells, TGF-b and IL-
10R were injected after mucosal application of the chimer and/or
poly-sensitization in mice (Fig. 7A). Indeed, each of these
antibodies significantly abrogated the suppressive effect of the
chimer pretreatment, indicating that CD25
+-T cells, TGF-b as
well as IL-10 play a potential role in immunomodulation for the
prevention of BPRFA. Consistent with this, a study in house dust
mite allergic patients showed that application of IL-10 and TGF-
b blocking antibodies in vitro abrogated the immunosuppressive
effects of CD4
+CD25
+-T cells induced by SIT [32].
Figure 7. Effects of blocking antibodies. (A) Effects of anti-TGF-b, anti-IL-10R and anti-CD25 on levels of IL-5 and IL-4 in supernatants of antigen-
stimulated spleen cell cultures. (B) Effects of anti-TGF-b on total and antigen-specific IgA production in sera. Chimer-pretreated mice treated with
isotype control antibody (black bars) in comparison with chimer-pretreated and anti-TGF-b treated mice (grey bars), anti-IL10R treated mice (striped
bars) and anti-CD25 treated mice (dotted bars). Poly-sensitized control group (white bars). *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0039409.g007
Figure 8. Characterization of Treg cells by Treg suppression assay. Suppressive activity of Treg cells derived from chimer-treated mice (black
bars) and poly-sensitized controls (white bars). Purified CD4
+CD25
2 T effector cells (Teff) and CD4
+CD25
+ T regulatory cells (Treg) were obtained by
cell sorting (MACS), then cultured alone or cocultured in three different ratios (Treg:Teff: 1:2, 1:8, 1:16) in combination with irradiated splenocytes and
stimulated by anti-CD3 antibody, before pulsing with [
3H] thymidine. The percent suppression mediated by Treg cells is calculated by the following
formula: [(cpm of Teff alone – cpm of Teff treated with Treg)/cpm of Teff cells alone]*100.
doi:10.1371/journal.pone.0039409.g008
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39409Allergic diseases have been linked with deficiency in function of
Tregs [33]. Indeed we have shown that chimer-induced Tregs
have higher suppression potential in comparison to Tregs derived
from poly-sensitized mice (Fig. 8).
Taken together, we constructed an allergen-chimer for pre-
vention of multiple sensitizations to pollen and pollen-related food
allergens. We demonstrated that mucosally applied chimers
covering important pollen and food-related epitopes can be used
to down-regulate/prevent systemic and local allergic immune
responses to all allergens, most likely by a combined induction of
regulatory pathways and Th1-biased immune responses. Such
mucosal allergen constructs might therefore provide promising
new tools for mucosal intervention against different levels of multi-
sensitization, including the birch pollen-related food allergy.
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